These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27384480)

  • 21. Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
    Jukna A; Montanari G; Mengoli MC; Cavazza A; Covi M; Barbieri F; Bertolini F; Rossi G
    J Thorac Oncol; 2016 Apr; 11(4):e49-51. PubMed ID: 26746366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
    Yu HA; Arcila ME; Rekhtman N; Sima CS; Zakowski MF; Pao W; Kris MG; Miller VA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2013 Apr; 19(8):2240-7. PubMed ID: 23470965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
    Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
    Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
    Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
    Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.
    Nam Y; Kim HC; Kim YC; Jang SH; Lee KY; Lee SY; Lee SH; Lee SY; Yoon SH; Ryu JS; Jang TW; Chang YS; Kim SJ; Park CK; Lee JE; Jung CY; Choi CM
    Thorac Cancer; 2021 Mar; 12(6):890-898. PubMed ID: 33529490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
    Kogure Y; Shigematsu F; Oki M; Saka H
    In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.
    Koyama K; Miura S; Watanabe S; Shoji S; Koshio J; Hayashi Y; Ishikawa D; Sato K; Miyabayashi T; Okajima M; Ota T; Tanaka T; Matsumoto N; Kuriyama H; Abe T; Nozaki K; Ichikawa K; Kondo R; Tanaka H; Kikuchi T
    Sci Rep; 2022 Apr; 12(1):6367. PubMed ID: 35430596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
    Goag EK; Lee JM; Chung KS; Kim SY; Leem AY; Song JH; Jung JY; Park MS; Chang YS; Kim YS; Chang J; Kim EY
    J Cancer; 2018; 9(6):1113-1120. PubMed ID: 29581791
    [No Abstract]   [Full Text] [Related]  

  • 37. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
    Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
    Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
    J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.
    Kim T; Choe J; Shin SH; Jeong BH; Lee K; Kim H; Lee SH; Um SW
    PLoS One; 2024; 19(9):e0310079. PubMed ID: 39298415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.